Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study

SIMPLE SUMMARY: Cardiotoxicity is a known adverse effect of Carfilzomib therapy; nevertheless, limited data are available on the comparison of the cardiovascular complications induced by Carfilzomib-dexamethasone versus Carfilzomib-lenalidomide-dexamethasone in patients with multiple myeloma (MM) in...

Descripción completa

Detalles Bibliográficos
Autores principales: Astarita, Anna, Mingrone, Giulia, Airale, Lorenzo, Cesareo, Marco, Colomba, Anna, Catarinella, Cinzia, Leone, Dario, Gay, Francesca, Bringhen, Sara, Veglio, Franco, Milan, Alberto, Vallelonga, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913715/
https://www.ncbi.nlm.nih.gov/pubmed/36765915
http://dx.doi.org/10.3390/cancers15030955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913715/
https://www.ncbi.nlm.nih.gov/pubmed/36765915
http://dx.doi.org/10.3390/cancers15030955

Ejemplares similares